ASLAN Pharmaceuticals Current Ratio 2017-2021 | ASLN

ASLAN Pharmaceuticals current ratio from 2017 to 2021. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
ASLAN Pharmaceuticals Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2021-06-30 $0.10B $0.01B 18.50
2021-03-31 $0.10B $0.01B 18.31
2020-12-31 $0.02B $0.01B 1.46
2020-09-30 $0.01B $0.01B 2.00
2020-06-30 $0.01B $0.00B 3.23
2020-03-31 $0.02B $0.00B 4.47
2019-12-31 $0.02B $0.01B 4.14
2019-09-30 $0.00B 0.00
2019-06-30 $0.00B 0.00
2019-03-31 $0.02B $0.01B 3.80
2018-12-31 $0.03B $0.01B 3.64
2018-09-30 $0.04B $0.01B 5.19
2018-06-30 $0.05B $0.01B 7.86
2018-03-31 $0.03B $0.02B 1.92
2017-12-31 $0.05B $0.01B 8.47
2017-09-30 $0.06B $0.00B 25.45
2017-06-30 $0.07B $0.00B 18.10
2017-03-31 $0.05B $0.00B 10.89
2016-12-31 $0.05B $0.00B 13.97
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.056B $0.003B
ASLAN Pharmaceuticals Limited operates as a clinical-stage biotechnology company. It develops drugs, medicines and novel therapeutics for the treatment of patients with oncology, respiratory and inflammatory diseases. The company's product portfolio includes Varlitinib, ASLAN004, ASLAN002 and ASLAN003 both are in clinical stage. ASLAN Pharmaceuticals Limited is based in Singapore.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $127.994B 8.52
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.309B 20.85
Biohaven Pharmaceutical Holding (BHVN) United States $9.150B 0.00
Emergent Biosolutions (EBS) United States $2.677B 6.46
Arcus Biosciences (RCUS) United States $2.522B 0.00
Myovant Sciences (MYOV) United Kingdom $1.905B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.799B 0.00
Zymeworks (ZYME) Canada $1.071B 0.00
Ambrx Biopharma (AMAM) United States $0.474B 0.00
SQZ Biotechnologies (SQZ) United States $0.341B 0.00
Enzo Biochem (ENZ) United States $0.160B 15.76